Abstract:Background: Autosomal dominant polycystic kidney disease (ADPKD) is the most prevalent genetic kidney disorder. While metformin has demonstrated the ability to inhibit cyst growth in animal models of ADPKD via activation of adenosine monophosphate-activated protein kinase (AMPK), its effectiveness in humans is limited due to its low potency. This study explored the impact of HL156A, a new and more potent AMPK activator, in a mouse model of ADPKD. Methods: To investigate whether HL156A inhibits the proliferation of renal cyst cells in ADPKD in vitro, exogenous human telomerase reverse transcriptase (hTERT)-immortalized renal cyst cells from ADPKD patients were treated with HL156A, and an MTT (dimethylthiazol-diphenyltetrazolium bromide) assay was performed. To assess the cyst-inhibitory effect of HL156A in vivo, we generated Pkd1 conditional knockout (KO) mice with aquaporin 2 (AQP2)-Cre, which selectively expresses Cre recombinase in the collecting duct. The effectiveness of HL156A in inhibiting cyst growth and improving renal function was confirmed by measuring the number of cysts and blood urea nitrogen (BUN) levels in the collecting duct-specific Pkd1 KO mice. Results: When cyst cells were treated with up to 20 µM of metformin or HL156A, HL156A reduced cell viability by 25% starting at a concentration of 5 µM, whereas metformin showed no effect. When AQP2-Cre male mice were crossed with Pkd1flox/flox female mice, and when AQP2-Cre female mice were crossed with Pkd1flox/flox male mice, the number of litters produced by both groups was comparable. In collecting duct-specific Pkd1 KO mice, HL156A was found to inhibit cyst growth, reducing both the number and size of cysts. Furthermore, it was confirmed that kidney function improved as HL156A treatment led to a reduction in elevated BUN levels. Lastly, it was observed that the increase in AMPK phosphorylation induced by HL156A decreased ERK phosphorylation and α-SMA expression. Conclusion: HL156A has potential as a drug that can restore kidney function in ADPKD patients by inhibiting cyst growth.

Inhibition of Pkhd1 May Cause S-Phase Entry Via Mtor Signaling Pathway

Rapamycin Reduces Podocyte Apoptosis and is Involved in Autophagy and Mtor/ P70S6K/4EBP1 Signaling.

Rapamycin prevents early steps of the development of diabetic nephropathy in rats.

A Rare Deep Intronic Mutation of PKHD1 Gene, C.8798-459 C > A, Causes Autosomal Recessive Polycystic Kidney Disease by Pseudoexon Activation

Inhibiting Focal Adhesion Kinase Ameliorates Cyst Development in Polycystin-1-Deficient Polycystic Kidney Disease in Animal Model

Inflammation Is More Sensitive than Cell Proliferation in Response to Rapamycin Treatment in Polycystic Kidney Disease

Recent Advances of mTOR Inhibitors Use in Autosomal Dominant Polycystic Kidney Disease: Is the Road Still Open?

Protein Kinase A Downregulation Delays the Development and Progression of Polycystic Kidney Disease

Inhibiting 4E-BP1 Re-Activation Represses Podocyte Cell Cycle Re-Entry and Apoptosis Induced by Adriamycin

Cystogenesis in ARPKD results from increased apoptosis in collecting duct epithelial cells of Pkhd1 mutant kidneys.

In vitro delivery of mTOR inhibitors by kidney-targeted micelles for autosomal dominant polycystic kidney disease

Protein Phosphatase 1α Interacts with a Novel Ciliary Targeting Sequence of Polycystin‐1 and Regulates Polycystin‐1 Trafficking

Phosphoproteome Profiling Revealed The Importance Of Mtor Inhibition On Cdk1 Activation To Further Regulate Cell Cycle Progression

Cyclin-dependent kinase 4 drives cystic kidney disease in the absence of mTORC1 signaling activity

Defects of renal tubular homeostasis and cystogenesis in the Pkhd1 knockout

Modulation of polycystic kidney disease by G-protein coupled receptors and cyclic AMP signaling

Modulation of Polycystic Kidney Disease Severity by Phosphodiesterase 1 and 3 Subfamilies

HL156A, an AMP-Activated Protein Kinase Activator, Inhibits Cyst Growth in Autosomal Dominant Polycystic Kidney Disease

A RhoA–YAP–c-Myc signaling axis promotes the development of polycystic kidney disease

SCF-SKP2 E3 ubiquitin ligase links mTORC1/ER stress/ISR with YAP activation in murine renal cystogenesis

Aquaporin‐3 Deficiency Slows Renal Cystogenesis Via Regulation of AMPK/ERK/mTOR Signaling